Onconic Therapeutics, established in 2020 and based in Seoul, South Korea, is an innovative biopharmaceutical company focused on developing advanced cancer treatments and gastrointestinal therapies. As a subsidiary of Jeil Pharma Holdings, Onconic has made notable progress with its flagship product, Jaqbo (Zastaprazan), which is designed to treat gastroesophageal reflux disease (GERD) and represents Korea's 37th domestically developed new drug.

"Focus on high-need therapeutic areas: The company specializes in developing novel treatments for oncology and gastrointestinal disorders, targeting areas with significant unmet medical needs Next-generation drug development: Onconic is working on advanced therapies such as Nesuparib, a double-targeted anticancer drug candidate, and JAQBO (zastaprazan), a next-generation potassium-competitive acid blocker (P-CAB)"

Private

Biotech, Pharma